Cascade Investment Advisors Inc. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,275 shares of the biopharmaceutical company’s stock after buying an additional 16 shares during the period. Regeneron Pharmaceuticals accounts for 1.2% of Cascade Investment Advisors Inc.’s holdings, making the stock its 22nd largest holding. Cascade Investment Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,635,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. NewSquare Capital LLC raised its position in Regeneron Pharmaceuticals by 1,450.0% in the first quarter. NewSquare Capital LLC now owns 31 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 29 shares during the last quarter. Sunbelt Securities Inc. bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $25,000. Householder Group Estate & Retirement Specialist LLC increased its position in Regeneron Pharmaceuticals by 1,750.0% in the 1st quarter. Householder Group Estate & Retirement Specialist LLC now owns 37 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 35 shares during the period. Steward Financial Group LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Finally, Manchester Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 740.0% during the first quarter. Manchester Capital Management LLC now owns 42 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 37 shares during the period. Institutional investors own 84.15% of the company’s stock.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 12,280 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $839.97, for a total value of $10,314,831.60. Following the completion of the transaction, the director now directly owns 2,037 shares of the company’s stock, valued at approximately $1,711,018.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Christine A. Poon sold 12,280 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $839.97, for a total transaction of $10,314,831.60. Following the completion of the sale, the director now directly owns 2,037 shares in the company, valued at $1,711,018.89. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $736.59, for a total transaction of $73,659.00. Following the transaction, the director now owns 18,647 shares in the company, valued at approximately $13,735,193.73. The disclosure for this sale can be found here. Insiders have sold a total of 32,171 shares of company stock valued at $26,982,965 over the last three months. 8.83% of the stock is currently owned by insiders.
Regeneron Pharmaceuticals Stock Performance
Shares of NASDAQ REGN traded down $14.06 during midday trading on Tuesday, reaching $803.97. The company’s stock had a trading volume of 127,135 shares, compared to its average volume of 582,346. The stock has a market capitalization of $87.28 billion, a P/E ratio of 21.62, a PEG ratio of 2.45 and a beta of 0.19. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.45 and a quick ratio of 4.64. The firm has a 50 day moving average price of $807.98 and a 200-day moving average price of $780.00. Regeneron Pharmaceuticals, Inc. has a 12-month low of $668.00 and a 12-month high of $847.50.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $10.24 earnings per share for the quarter, topping the consensus estimate of $8.48 by $1.76. The business had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.02 billion. Regeneron Pharmaceuticals had a return on equity of 19.19% and a net margin of 33.93%. The business’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $9.77 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.42 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages have commented on REGN. Wells Fargo & Company lifted their target price on Regeneron Pharmaceuticals from $875.00 to $980.00 and gave the stock an “overweight” rating in a report on Monday, August 21st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $800.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, September 21st. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the stock from $720.00 to $992.00 in a research report on Monday, August 21st. 22nd Century Group reiterated a “downgrade” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 28th. Finally, Guggenheim lowered their target price on shares of Regeneron Pharmaceuticals from $935.00 to $900.00 in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twenty-one have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $900.92.
Check Out Our Latest Research Report on REGN
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.